Providing pre-exposure prophylaxis (PrEP) to people who need it entails at least nine key steps, which can be conceived of as a PrEP continuum of care, according to an article published online ahead of print by Amy Nunn and colleagues in AIDS. This continuum can ...

Targeting chronic hepatitis B infections affecting more than 240 million people worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (January 17) that it has entered into a research collaboration agreement with Georgia State University Research Foundation (GSU) to advance the ...

Researchers at University of California San Diego School of Medicine, with colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Manitoba and St. Boniface Hospital Albrechtsen Research Centre in Canada, have identified a molecular signaling pathway that, when blocked, ...

DPP® HIV-Syphilis Assay on track for U.S. regulatory submission in 2017 MEDFORD, N.Y., Jan. 17, 2017 — Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received a CE mark for its DPP® HIV-Syphilis combination assay. ...

GENEVA, 17 January – UNITAID is calling for proposals to create and accelerate the demand for and adoption of HIV self-testing (HIVST) in low and middle-income countries, particularly among underserved populations at high risk of HIV infection. While access to HIV testing services has increased significantly ...

A questionnaire from the president-elect’s transition team asked whether the extraordinarily successful PEPFAR had become a “massive, international entitlement program,” and whether it was worth the investment. In 2003, in a move that has been described as his greatest legacy, George W. Bush created a program ...

Prohibition can prevent access to harm reduction treatment, including methadone, for people who inject drugs, writes Michel Kazatchkine Why is eastern Europe the only region in the world that still has a growing HIV epidemic?1 In one of the region’s countries, Russia, more than two thirds ...

The antiretroviral drugs used to treat HIV infection might inadvertently be boosting gay/bisexual men’s susceptibility to the bacteria responsible for syphilis, Treponema pallidum, conclude researchers in the journal Sexually Transmitted Infections. This might explain why new and repeat cases in these groups have risen so sharply ...

Great advances in science often come from outside the direct field of research. Since the early days of the epidemic, the HIV research community brought together clinicians, virologists, social scientists, and community members to try to shed light on the devastating disease. More than 30 years ...

The vast majority of people taking antiretroviral therapy (ART) in the UK have an accurate knowledge of their current viral load (VL) level, investigators report in HIV Medicine. Overall, 96% of people who told researchers their viral load was undetectable had a clinic-recorded viral load ...

On January 16 the Scottish Medicines Consortium (SMC) published advice accepting Zepatier for routine use in NHS Scotland. Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic hepatitis C. Elbasvir-grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and ...

There are a number of things that can impact our immune system’s ability to eliminate a virus; the expression levels of particular proteins—specifically interferon proteins—is one of them. In the past, human type I interferons (IFNs), a large subgroup of interferon proteins, were thought to ...

Supplement to consolidated guidelines on HIV testing services Since the release of the consolidated guidelines in 2015, new evidence has emerged. Consequently, in an effort to further support countries, programme managers, health workers and other stakeholders seeking to achieve national and international HIV goals, this 2016 ...

The January issue of the Journal includes papers on a range of topics and reports from two recent meetings – the Ghent HIV Reservoir Characterization Symposium and the Third Biennial Strategies for an HIV Cure Meeting. To read an overview of the issue, click here. The January ...

Last month’s announcement that the Bill and Melinda Gates Foundation will give up to $140 million to a Boston drug device manufacturer to develop an implantable mini-pump to deliver drugs for pre-exposure prophylaxis (PrEP) against HIV infection has focused attention on the future of PrEP. ...

Washington, DC – January 13, 2017 – A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century. With the rise of multidrug resistant tuberculosis, the difficulty of curing the ...

Eight weeks of treatment with AbbVie’s investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for chronic hepatitis C achieved high SVR rates in genotype 1 Japanese patients. – 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR with 8 weeks of ...

In the context of its mandate expansion into tuberculosis, the Medicines Patent Pool (MPP) was asked by its funder, UNITAID, to conduct a study to examine how MPP licences could contribute to addressing some of the stewardship challenges for new drugs for tuberculosis, specifically for ...